Lobbyists. Revolving doors. Congressional stock trades. Regulatory capture. The system isn’t broken — it’s working exactly as the people who built it intended.
The revolving door between government and industry is not a metaphor — it’s a career path. Congressional staffers, agency officials, and former legislators routinely trade their government access for seven-figure lobbying salaries. The contacts they built on the public dime become their product.
These are not hypothetical examples. They are documented, public record cases that illustrate exactly how regulatory expertise built in government gets monetized in industry — often against the very public interest those officials were paid to protect.
The STOCK Act was passed in 2012 to address insider trading by members of Congress. The fine for violations: $200. The number of criminal prosecutions since 2012: zero. Members of Congress routinely trade in companies they directly regulate — and the penalty for getting caught is less than a parking ticket.
The STOCK Act required disclosure within 45 days. It did not ban trading. It did not require divestment. It did not close the family member loophole. The fine for violations is $200 — less than a minor traffic ticket in most states. This is not oversight. This is the appearance of oversight.
Regulatory capture is when a regulatory agency advances the interests of the industry it was created to oversee instead of the public. It doesn’t require corruption or scandal. It requires only that the people who understand an industry well enough to regulate it are the same people who built careers inside it.
| Agency | Supposed to Regulate | What Actually Happens |
|---|---|---|
| FDA | Drug and food safety | Accelerated approvals for drugs with minimal trial data; user fee funding model aligns agency revenue with industry approvals |
| FAA | Aviation safety | Delegated Boeing 737 MAX safety certification to Boeing itself; two crashes, 346 dead |
| EPA | Environmental protection | Industry representatives serve on advisory panels that set enforcement priorities and emission standards |
| CFPB | Consumer financial protection | Funding and authority have been contested by financial industry-backed officials since 2017; enforcement dramatically reduced |
| FCC | Telecom regulation | Net neutrality repealed under chairman who came directly from Verizon; reinstated and repealed cyclically |
| OSHA | Workplace safety | One inspector per 70,000 workers; inspection rates at historic lows; penalties average $13,000 per citation |
Political spending is not altruism. It is the most profitable investment most corporations make. Studies consistently show that every dollar spent on lobbying returns $220 in tax benefits, contract awards, or favorable regulatory outcomes. That math explains everything about who spends and how much.
In 2004, the American Jobs Creation Act included a one-time tax repatriation provision. Companies lobbying for it spent $282M and received $100B in tax savings. That is a documented 22,000% return on investment.
The pharmaceutical industry spent $373M lobbying against Medicare drug price negotiation in 2021. They successfully delayed the policy by two years, preserving an estimated $80B+ in revenue during that window.
The gap between what the lobbying class spends and what the average American has access to is not just a financial story — it’s a representation story. When the architecture of influence is built for those with capital, the policies that emerge from that architecture will reflect whose calls get returned.
The FDA official who approved OxyContin in 1995 left the agency in 1997 and was working at Purdue Pharma by late 1998. The FAA delegated Boeing 737 MAX safety certification to Boeing itself. After RFK Jr. removed senior FDA officials in 2025, they immediately went to Eli Lilly, Pfizer, Merck, Roche, and Novartis. This is the system operating as designed.